Back to search

National and Kapodistrian University of Athens

Η μελέτη των μορίων αγγειογένεσης και επιδιόρθωσης του DNA σε ασθενείς με μονοκλωνική γαμμαπάθεια αδιευκρίνιστης σημασίας (MGUS) και ασυμπτωματικό πολλαπλούν μυέλωμα

Abstract

dc:description

Regarding the role of key components of angiogenesis, the angiogenic cytokines in evolution of MM has not been fully investigated. Overall the relevant studies suggest that induction of angiogenesis is a feature of, and possible important in the transformation of MGUS to MM, and in the progression of early stage myeloma to advanced, refractory disease. It is crucial not only to identify which of these factors is important to angiogenesis of MM, but also to make available a useful tool of early prediction of symptomatic disease, that requires treatment. We therefore, measured the concentration of 4 factors that have a well-established angiogenic potential such as VEGF, ANG, ang-1 and -2. In our study, compared to healthy controls and patients with pre-cursor stages of MGUS and SMM, the myeloma patients presented increased levels of ang-2 in serum. In addition, the ratio of ang-1/ang-2 was found reduced in symptomatic patients in compared to health individuals and the 2 other groups of patients. According to our previous study, the reduced ratio of ang-1/ang-2 has been correlated with advanced disease features and poor survival of MM patients who received antimyeloma novel agents 16. Although that is already known that ang-2 is the natural antagonist of ang-1, and blocks ang-1 mediated Tie2 activation on endothelial cells and induces vessel destabilization, it still remains unclear the source of ang-2. As it has been previously demonstrated that myeloma cells lack expression of ang-2 mRNA and protein probably the increased levels of ang-2, according our data could be attributed to endothelial vascular cells production , as ang-2 facilitates endothelial production in response to VEGF that induce angiogenesis, constituting a vicious cycle.VEGF was also found increased in patients with MM and in all pre-malignant stages, indicating the angiogenic background of the disease. The absence of statistical significance between the healthy controls and the patients with MGUS, could be explained by the occurrence of angiogenic switch in stage of SMM and not earlier. The angiogenic switch is the loss of balance between the pro- and anti-angiogenic stimuli. In addition, the expected increase of tumor burden from stage of MGUS to symptomatic MM, could be responsible for these high levels of VEGF, as CD138+ myeloma cells express VEGF mRNA in almost all patients (80-90%) and high levels of this factor are also found in BM samples of them.Briefly, in these studies chromatin condensation, transcription activity and DNA damage response pathways (melphalan-induced DNA damage repair in four genomic loci including beta-actin, p53, N-ras and delta-globin genes, inhibition of RNA synthesis, accumulation of p53 protein and induction of apoptosis) were measured in PBMCs and plasma cells from patients with MGUS, SMM and MM (Responders and Non Responders to melphalan therapy). In agreement with previous studies, we found that beta-actin, p53 and N-ras genes were transcriptionally active while delta-globin gene was silent in all samples from healthy volunteers and MGUS patients. However, an induction of the transcription activity of delta-globin gene was found in ~45% of SMM and ~80% of symptomatic MM patients. Also, in both PBMCs and plasma cells the local looseness of the chromatin structure and the repair efficiency varied in the order: MGUS<SMM<MM-Responders<MM-Non-Responders. Also, since melphalan adducts can act as blocks for the elongation of RNA polymerases, we found that the intensity and the duration of both total RNA and mRNA synthesis varied in the order: Normal cells>MGUS>SMM>MM-Responders>MM-Non Responders. Moreover, in both PBMCs and plasma cells, the accumulation of p53 and the induction of apoptosis were suppressed during cancer progression, i.e. from MGUS to SMM and then to MM. Interestingly, a further suppression of both the accumulation of p53 and the induction of apoptosis was obtained as we go from MM-Responders to MM-Non Responders to melphalan therapy. These results suggest that myelomagenesis is associated with epigenetic changes and DNA damage response pathways alterations that can be used as novel molecular biomarkers for early diagnosis of the disease and prediction of clinical outcome.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Gkotzamanidou, Maria
  • Γκοτζαμανίδου, Μαρία

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40295

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Gkotzamanidou, Maria; Γκοτζαμανίδου, Μαρία. Η μελέτη των μορίων αγγειογένεσης και επιδιόρθωσης του DNA σε ασθενείς με μονοκλωνική γαμμαπάθεια αδιευκρίνιστης σημασίας (MGUS) και ασυμπτωματικό πολλαπλούν μυέλωμα. National and Kapodistrian University of Athens, 2013. http://hdl.handle.net/10442/hedi/40295